Respiratory Antivirals Market 2027 By Disease Type, Drug Class | The Insight Partners

Respiratory Antivirals Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Disease Type (Influenza, Pneumonia, Bronchiolitis, Croup, Measles, Upper Respiratory Tract Infections (URTIs), Others); Drug Class (Neuraminidase Inhibitors, Ion Channel Blockers, Nucleoside Analogs, Fusion Protein Inhibitors)

Report Code: TIPRE00016904 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Respiratory antivirals are a class of medications that are used to treat viral infections of the respiratory system. Most viral infections resolve spontaneously in immunocompetent individuals. Antiviral therapy aims to minimize symptoms and infectivity as well as to shorten the duration of illness. These drugs act by arresting the viral replication cycle at various stages.

MARKET DYNAMICS

Factors driving the growth of the respiratory antivirals market are the growing incidences of respiratory infections, coupled with technological advancements such as use of nanotechnology in virology. However, the uncertainties in the regulatory guidelines is expected to hamper the growth of the market. Moreover, increasing demand for quality healthcare and favorable policies for treatment and prevention of respiratory viral diseases is anticipated to boost the market growth.

MARKET SCOPE

The "Respiratory Antivirals Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of respiratory antivirals market with detailed market segmentation by disease type and drug class. The respiratory antivirals market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in respiratory antivirals market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The respiratory antivirals market is segmented on the basis of disease type and drug class. Based on disease type, the market is segmented as influenza, pneumonia, bronchiolitis, croup, measles, upper respiratory tract infections (URTIS), and others. On the basis of drug class, the market is categorized as neuraminidase inhibitors, ion channel blockers, nucleoside analogs, and fusion protein inhibitors. Neuraminidase inhibitors divided as zanamivir and oseltamivir. Ion channel blockers divided as rimantadine and amantadine. Nucleoside analogs divided as ribavirin and aciclovir. Fusion protein inhibitors divided as pavilizumab.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the respiratory antivirals market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The respiratory antivirals market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting respiratory antivirals market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the respiratory antivirals market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the respiratory antivirals market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from respiratory antivirals market are anticipated to have lucrative growth opportunities in the future with the rising demand for respiratory antivirals in the global market. Below mentioned is the list of few companies engaged in the respiratory antivirals market.

The report also includes the profiles of key players in respiratory antivirals market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Takeda Pharmaceutical Company Limited
  •  Pfizer, Inc.
  •  GlaxoSmithKline plc
  •  Mylan Inc.
  •  Merck & Co., Inc.
  •  AstraZeneca plc.
  •  F. Hoffmann-La Roche Ltd.
  •  Novartis AG
  •  Teva Pharmaceutical Industries Ltd.
  •  Sun Pharmaceutical Industries Ltd.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Respiratory Antivirals Market - By Disease Type
1.3.2 Respiratory Antivirals Market - By Drug Class
1.3.3 Respiratory Antivirals Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RESPIRATORY ANTIVIRALS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RESPIRATORY ANTIVIRALS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RESPIRATORY ANTIVIRALS MARKET - GLOBAL MARKET ANALYSIS
6.1. RESPIRATORY ANTIVIRALS - GLOBAL MARKET OVERVIEW
6.2. RESPIRATORY ANTIVIRALS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. RESPIRATORY ANTIVIRALS MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE TYPE
7.1. OVERVIEW
7.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
7.3. INFLUENZA
7.3.1. Overview
7.3.2. Influenza Market Forecast and Analysis
7.4. PNEUMONIA
7.4.1. Overview
7.4.2. Pneumonia Market Forecast and Analysis
7.5. BRONCHIOLITIS
7.5.1. Overview
7.5.2. Bronchiolitis Market Forecast and Analysis
7.6. CROUP
7.6.1. Overview
7.6.2. Croup Market Forecast and Analysis
7.7. MEASLES
7.7.1. Overview
7.7.2. Measles Market Forecast and Analysis
7.8. UPPER RESPIRATORY TRACT INFECTIONS (URTIS)
7.8.1. Overview
7.8.2. Upper Respiratory Tract Infections (URTIs) Market Forecast and Analysis
7.9. OTHERS
7.9.1. Overview
7.9.2. Others Market Forecast and Analysis
8. RESPIRATORY ANTIVIRALS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. NEURAMINIDASE INHIBITORS
8.3.1. Overview
8.3.2. Neuraminidase Inhibitors Market Forecast and Analysis
8.3.3. Zanamivir Market
8.3.3.1. Overview
8.3.3.2. Zanamivir Market Forecast and Analysis
8.3.4. Oseltamivir Market
8.3.4.1. Overview
8.3.4.2. Oseltamivir Market Forecast and Analysis
8.4. ION CHANNEL BLOCKERS
8.4.1. Overview
8.4.2. Ion Channel Blockers Market Forecast and Analysis
8.4.3. Rimantadine Market
8.4.3.1. Overview
8.4.3.2. Rimantadine Market Forecast and Analysis
8.4.4. Amantadine Market
8.4.4.1. Overview
8.4.4.2. Amantadine Market Forecast and Analysis
8.5. NUCLEOSIDE ANALOGS
8.5.1. Overview
8.5.2. Nucleoside Analogs Market Forecast and Analysis
8.5.3. Ribavirin Market
8.5.3.1. Overview
8.5.3.2. Ribavirin Market Forecast and Analysis
8.5.4. Aciclovir Market
8.5.4.1. Overview
8.5.4.2. Aciclovir Market Forecast and Analysis
8.6. FUSION PROTEIN INHIBITORS
8.6.1. Overview
8.6.2. Fusion Protein Inhibitors Market Forecast and Analysis
8.6.3. Pavilizumab Market
8.6.3.1. Overview
8.6.3.2. Pavilizumab Market Forecast and Analysis
9. RESPIRATORY ANTIVIRALS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Respiratory Antivirals Market Overview
9.1.2 North America Respiratory Antivirals Market Forecasts and Analysis
9.1.3 North America Respiratory Antivirals Market Forecasts and Analysis - By Disease Type
9.1.4 North America Respiratory Antivirals Market Forecasts and Analysis - By Drug Class
9.1.5 North America Respiratory Antivirals Market Forecasts and Analysis - By Countries
9.1.5.1 United States Respiratory Antivirals Market
9.1.5.1.1 United States Respiratory Antivirals Market by Disease Type
9.1.5.1.2 United States Respiratory Antivirals Market by Drug Class
9.1.5.2 Canada Respiratory Antivirals Market
9.1.5.2.1 Canada Respiratory Antivirals Market by Disease Type
9.1.5.2.2 Canada Respiratory Antivirals Market by Drug Class
9.1.5.3 Mexico Respiratory Antivirals Market
9.1.5.3.1 Mexico Respiratory Antivirals Market by Disease Type
9.1.5.3.2 Mexico Respiratory Antivirals Market by Drug Class
9.1.5.4 US Respiratory Antivirals Market
9.1.5.4.1 US Respiratory Antivirals Market by Disease Type
9.1.5.4.2 US Respiratory Antivirals Market by Drug Class
9.2. EUROPE
9.2.1 Europe Respiratory Antivirals Market Overview
9.2.2 Europe Respiratory Antivirals Market Forecasts and Analysis
9.2.3 Europe Respiratory Antivirals Market Forecasts and Analysis - By Disease Type
9.2.4 Europe Respiratory Antivirals Market Forecasts and Analysis - By Drug Class
9.2.5 Europe Respiratory Antivirals Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Respiratory Antivirals Market
9.2.5.1.1 Germany Respiratory Antivirals Market by Disease Type
9.2.5.1.2 Germany Respiratory Antivirals Market by Drug Class
9.2.5.2 France Respiratory Antivirals Market
9.2.5.2.1 France Respiratory Antivirals Market by Disease Type
9.2.5.2.2 France Respiratory Antivirals Market by Drug Class
9.2.5.3 Italy Respiratory Antivirals Market
9.2.5.3.1 Italy Respiratory Antivirals Market by Disease Type
9.2.5.3.2 Italy Respiratory Antivirals Market by Drug Class
9.2.5.4 Spain Respiratory Antivirals Market
9.2.5.4.1 Spain Respiratory Antivirals Market by Disease Type
9.2.5.4.2 Spain Respiratory Antivirals Market by Drug Class
9.2.5.5 United Kingdom Respiratory Antivirals Market
9.2.5.5.1 United Kingdom Respiratory Antivirals Market by Disease Type
9.2.5.5.2 United Kingdom Respiratory Antivirals Market by Drug Class
9.2.5.6 Rest of Europe Respiratory Antivirals Market
9.2.5.6.1 Rest of Europe Respiratory Antivirals Market by Disease Type
9.2.5.6.2 Rest of Europe Respiratory Antivirals Market by Drug Class
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Respiratory Antivirals Market Overview
9.3.2 Asia-Pacific Respiratory Antivirals Market Forecasts and Analysis
9.3.3 Asia-Pacific Respiratory Antivirals Market Forecasts and Analysis - By Disease Type
9.3.4 Asia-Pacific Respiratory Antivirals Market Forecasts and Analysis - By Drug Class
9.3.5 Asia-Pacific Respiratory Antivirals Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Respiratory Antivirals Market
9.3.5.1.1 Australia Respiratory Antivirals Market by Disease Type
9.3.5.1.2 Australia Respiratory Antivirals Market by Drug Class
9.3.5.2 China Respiratory Antivirals Market
9.3.5.2.1 China Respiratory Antivirals Market by Disease Type
9.3.5.2.2 China Respiratory Antivirals Market by Drug Class
9.3.5.3 India Respiratory Antivirals Market
9.3.5.3.1 India Respiratory Antivirals Market by Disease Type
9.3.5.3.2 India Respiratory Antivirals Market by Drug Class
9.3.5.4 Japan Respiratory Antivirals Market
9.3.5.4.1 Japan Respiratory Antivirals Market by Disease Type
9.3.5.4.2 Japan Respiratory Antivirals Market by Drug Class
9.3.5.5 South Korea Respiratory Antivirals Market
9.3.5.5.1 South Korea Respiratory Antivirals Market by Disease Type
9.3.5.5.2 South Korea Respiratory Antivirals Market by Drug Class
9.3.5.6 Rest of Asia-Pacific Respiratory Antivirals Market
9.3.5.6.1 Rest of Asia-Pacific Respiratory Antivirals Market by Disease Type
9.3.5.6.2 Rest of Asia-Pacific Respiratory Antivirals Market by Drug Class
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Respiratory Antivirals Market Overview
9.4.2 Middle East and Africa Respiratory Antivirals Market Forecasts and Analysis
9.4.3 Middle East and Africa Respiratory Antivirals Market Forecasts and Analysis - By Disease Type
9.4.4 Middle East and Africa Respiratory Antivirals Market Forecasts and Analysis - By Drug Class
9.4.5 Middle East and Africa Respiratory Antivirals Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Respiratory Antivirals Market
9.4.5.1.1 South Africa Respiratory Antivirals Market by Disease Type
9.4.5.1.2 South Africa Respiratory Antivirals Market by Drug Class
9.4.5.2 Saudi Arabia Respiratory Antivirals Market
9.4.5.2.1 Saudi Arabia Respiratory Antivirals Market by Disease Type
9.4.5.2.2 Saudi Arabia Respiratory Antivirals Market by Drug Class
9.4.5.3 U.A.E Respiratory Antivirals Market
9.4.5.3.1 U.A.E Respiratory Antivirals Market by Disease Type
9.4.5.3.2 U.A.E Respiratory Antivirals Market by Drug Class
9.4.5.4 Rest of Middle East and Africa Respiratory Antivirals Market
9.4.5.4.1 Rest of Middle East and Africa Respiratory Antivirals Market by Disease Type
9.4.5.4.2 Rest of Middle East and Africa Respiratory Antivirals Market by Drug Class
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Respiratory Antivirals Market Overview
9.5.2 South and Central America Respiratory Antivirals Market Forecasts and Analysis
9.5.3 South and Central America Respiratory Antivirals Market Forecasts and Analysis - By Disease Type
9.5.4 South and Central America Respiratory Antivirals Market Forecasts and Analysis - By Drug Class
9.5.5 South and Central America Respiratory Antivirals Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Respiratory Antivirals Market
9.5.5.1.1 Brazil Respiratory Antivirals Market by Disease Type
9.5.5.1.2 Brazil Respiratory Antivirals Market by Drug Class
9.5.5.2 Argentina Respiratory Antivirals Market
9.5.5.2.1 Argentina Respiratory Antivirals Market by Disease Type
9.5.5.2.2 Argentina Respiratory Antivirals Market by Drug Class
9.5.5.3 Rest of South and Central America Respiratory Antivirals Market
9.5.5.3.1 Rest of South and Central America Respiratory Antivirals Market by Disease Type
9.5.5.3.2 Rest of South and Central America Respiratory Antivirals Market by Drug Class
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL RESPIRATORY ANTIVIRALS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. RESPIRATORY ANTIVIRALS MARKET, KEY COMPANY PROFILES
12.1. TAKEDA PHARMACEUTICAL COMPANY LIMITED
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PFIZER, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. GLAXOSMITHKLINE PLC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. MYLAN INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. MERCK AND CO., INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ASTRAZENECA PLC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. F. HOFFMANN-LA ROCHE LTD.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. NOVARTIS AG
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SUN PHARMACEUTICAL INDUSTRIES LTD.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Takeda Pharmaceutical Company Limited
2. Pfizer, Inc.
3. GlaxoSmithKline plc
4. Mylan Inc.
5. Merck & Co., Inc.
6. AstraZeneca plc.
7. F. Hoffmann-La Roche Ltd.
8. Novartis AG
9. Teva Pharmaceutical Industries Ltd.
10. Sun Pharmaceutical Industries Ltd.
TIPRE00016904
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking